Biotech company Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM) today confirmed the positive outlook for its lead product, recombinant human C1 inhibitor (rhC1INH) in Phase III clinical trials for the treatment of hereditary angioedema (HAE). The clinical results of rhC1INH were presented at an international investigators meeting in Paris with participation of over 25 clinical centers from Europe, US, and Canada.
